Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS), a clinical-stage precision oncology company developing a ...

Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose. “Tuspetinib brings favorable safety and broad activity across AML genetic subtypes to the TUS+VEN+AZA triplet therapy ...